GlaxoSmithKline to Complete Novartis Deal in March
26 February 2015 - 4:02AM
Dow Jones News
LONDON--Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) said
Wednesday that it now expects to complete its three-part
transaction with Novartis AG (NOVN.VX) in the week commencing March
2, following good progress on obtaining clearances and regulatory
approvals.
The three-part transaction with Novartis includes Glaxo's
acquisition of Novartis's vaccines business, the creation of a
consumer healthcare joint venture and the divestment to Novartis of
GlaxoS's Oncology portfolio.
Shares of GlaxoS at 1628 GMT trading 0.1% lower at 1,545
pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024